Shares of this Indian mid-cap pharmaceutical company jumped on getting approval from USFDA 

Shares of this Indian mid-cap pharmaceutical company jumped on getting approval from USFDA 

by 5paisa Research Team Last Updated: Mar 11, 2023 - 12:17 pm 806 Views
Listen icon

Shares are up today by more than 2% after the company announced about the development.


About the Approval

The United States Food and Drug Administration (USFDA) has given Erythromycin Tablets USP, 250 mg and 500 mg its final clearance (USRLD: Erythromycin Tablets). Including respiratory tract infections, skin infections, diphtheria, intestinal amebiasis, acute pelvic inflammatory disease, legionnaire's disease, pertussis, and syphilis, erythromycin tablets USP, 250 mg and 500 mg are used to prevent and treat infections in many different sections of the body.


The group's formulation manufacturing plant in Moraiya, Ahmedabad, will produce the medications (India). Sales of erythromycin tablets USP, 250 mg and 500 mg totaled $25.1 million per year in the US (IQVIA MAT Dec. 2022). The group has so far submitted approximately 440 ANDAs since the filing procedure began in FY 2003–2004, and it now has 350 approvals.


Share price movement of Zydus Lifesciences Ltd 
Scrip opened today at Rs 468.95 and made its day high at Rs 478.50. The 52-week high of the stock is Rs 482.20, whereas the 52-week low was Rs 319.40. Promoters hold 74.98%, whereas institutional and non-institutional holdings are 16.20% and 8.81%, respectively. Presently, the market cap of the company is Rs 48,358.05 crore.

Company profile 

Cadila Healthcare was established in 1995 under the auspices of the Zydus group after the business underwent restructuring. The group's revenue increased significantly from its modest turnover of Rs 250 crore in 1995 to over Rs. 14,253 crore in FY20, reflecting the group's considerable financial expansion. 

Zydus continues to develop with an unwavering emphasis on meeting the unmet healthcare requirements, staying true to its brand promise of being committed to life in all of its aspects. Meanwhile, it recommits to its goal of building happier, healthier communities all throughout the world. 

Share Market Today


How do you rate this article?

Start Investing in 5 mins*

Rs. 20 Flat Per Order | 0% Brokerage

378X91-D3

About the Author

Our research team is composed of some highly qualified research professionals, their expertise range across sectors.

Disclaimer

Investment/Trading in securities Market is subject to market risk, past performance is not a guarantee of future performance. The risk of loss in trading and investment in Securities markets including Equites and Derivatives can be substantial.
Enjoy 0%* Brokerage with 5paisa
Resend OTP
Please Enter OTP
Mobile No. belongs to

By proceeding, you agree to the T&C.

Latest News
Trust Fintech IPO Subscribed 108.63 times

Trust Fintech IPO is book-built issue of ₹63.45 crores, consisting entirely of fresh issue shares totalling 62.82 lakh. Trust Fintech IPO commenced its subscription period on March 26, 2024, & concludes today, March 28, 2024.

Aspire & Innovative IPO Subscribed 15.17 times

Aspire & Innovative IPO is a book built issue of Rs 21.97 crores. The issue comprises entirely a fresh issue of 40.68 lakh shares. Aspire & Innovative IPO opens for subscription on March 26, 2024, and closes on March 28, 2024. The allotment for the Aspire & Innovative IPO is expected to be finalized on Monday, April 1, 2024.

Blue Pebble IPO Subscribed 56.32 times

Blue Pebble IPO, valued at ₹18.14 crores, comprises fresh issue of 10.8 lakh shares. Commencing subscription on March 26, 2024, Blue Pebble IPO is set to conclude on March 28, 2024. Allotment process is scheduled to be finalized by Monday, April 1, 2024. Following this, IPO is slated to debut on NSE SME, with tentative listing date of Wednesday, April 3, 2024.